Babesia canis merozoite surface antigen 1 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Babesia canis merozoite surface antigen 1 antibodies pairs and antigen for animal health (animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease babesiosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P261-Tg001-Ag01	Recombinant Babesia canis merozoite surface antigen 1 protein	$3090.00
GMP-VT-P261-Tg001-Ab01	Anti-Babesia canis merozoite surface antigen 1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P261-Tg001-Ab02	Anti-Babesia canis merozoite surface antigen 1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P261-Tg001-Ab03	Anti-Babesia canis merozoite surface antigen 1 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P261-Tg001-Ab04	Anti-Babesia canis merozoite surface antigen 1 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P261-Tg001-Ag01
Product Name	Recombinant Babesia canis merozoite surface antigen 1 protein
Pathogen	Babesia canis
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Babesia canis merozoite surface antigen 1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Babesia canis level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with babesiosis.
Tag	His
Product description	Recombinant Babesia canis merozoite surface antigen 1 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P261-Tg001-Ab01,GMP-VT-P261-Tg001-Ab02
Pathogen	Babesia canis
Product Name	Anti-Babesia canis merozoite surface antigen 1 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Babesia canis merozoite surface antigen 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Babesia canis antibodies in Babesia canis level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with babesiosis.
Product description	Anti-Babesia canis merozoite surface antigen 1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Babesia canis antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P261-Tg001-Ab03,GMP-VT-P261-Tg001-Ab04
Pathogen	Babesia canis
Product Name	Anti-Babesia canis merozoite surface antigen 1 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Babesia canis merozoite surface antigen 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Babesia canis antibodies in Babesia canis level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse infectious disease with babesiosis.
Product description	Anti-Babesia canis merozoite surface antigen 1 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Babesia canis is a tick-borne protozoan pathogen that primarily infects dogs. The pathogen belongs to the phylum Apicomplexa and the genus Babesia, which also includes other tick-borne pathogens such as Babesia microti and Babesia divergens.

Babesia canis is prevalent in many regions of the world, particularly in Europe and Asia. The pathogen is typically transmitted by the bite of infected ticks, with the most common vector being the brown dog tick Rhipicephalus sanguineus. While dogs are the primary host for Babesia canis, the pathogen has also been reported in other animals such as wolves, foxes, and even humans, although infections in these hosts are extremely rare.

Babesia canis can cause a range of diseases in dogs, with clinical manifestations ranging from mild, moderate, and severe acute disease, to subacute, chronic, and asymptomatic infections. Clinical signs may include fever, anemia, lethargy, and jaundice. In severe cases, the pathogen can lead to coagulopathy, thrombocytopenia, and organ failure. The severity of the disease often depends on the immune status of the host and the virulence of the Babesia strain.

The pathogenesis of Babesia canis involves several stages. Following transmission by ticks, the pathogen invades red blood cells and proliferates within them, leading to progressive hemolysis and anemia. The pathogen can also invade other tissues such as the spleen and liver, leading to organ damage. Babesia canis can modulate host immune responses, including cytokine production, to evade host immunity.

The genome of Babesia canis is comprised of several genes and proteins that are crucial for the pathogen's survival. The heat shock protein 70 (HSP70) and rhoptry-associated protein 1 (RAP1) are two important proteins involved in host cell invasion and immune evasion. The surface protein 25 (P25) is also a diagnostic target for Babesia canis.

Diagnosis of Babesia canis infections can be challenging, particularly in asymptomatic or subclinical infections. Major diagnostic methods include blood smear observation, serological assays, and PCR techniques that target the 18S rRNA gene sequence or other diagnostic targets. PCR assays have the advantage of high sensitivity and specificity in detecting low-level infections, but may require specialized equipment and technical expertise.

Treatment of Babesia canis infections typically involves administration of anti-protozoal drugs such as imidocarb dipropionate or atovaquone and azithromycin. However, the efficacy of these treatments may depend on the stage of disease and the virulence of the Babesia strain. Supportive care such as blood transfusions may also be necessary in severe cases.

In conclusion, Babesia canis is an important tick-borne pathogen that can cause a range of clinical manifestations in dogs. While diagnosis and treatment can be challenging, timely intervention and supportive care can improve outcomes in affected animals. Prevention measures such as tick control and regular veterinary visits can also play an important role in minimizing the impact of this pathogen.

About GDU